Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) have received a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $77.6667.

A number of brokerages recently commented on CORT. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a report on Wednesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. HC Wainwright reduced their target price on Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel — the regulatory win is the primary commercial catalyst and triggered the recent multi‑day rally due to survival benefit data and earlier‑than‑expected decision. FDA Approves (BusinessWire)
• Positive Sentiment: Analyst/firm support: multiple firms raised or reiterated positive views (Truist to “strong‑buy”, Canaccord price target increase reported, HC Wainwright kept a Buy rating), which supports upside potential as the market prices in Lifyorli’s commercial opportunity. Analyst Coverage (Benzinga)
• Positive Sentiment: Insider confidence signal: market commentary highlighted a mid‑March purchase by a director (~100,000 shares) that likely helped amplify bullish positioning ahead of the approval. Insider Buy Analysis (QuiverQuant)
• Neutral Sentiment: Market structure/volatility: trading was temporarily halted (LULD pause) and the name has posted very large intraday moves as investors re‑price the company; expect elevated volume and short‑term volatility. Market Reaction Coverage (Reuters)
• Negative Sentiment: Multiple securities‑class‑action firms have filed/issued alerts alleging misstatements tied to prior FDA issues and patent litigation — several firms are seeking lead plaintiffs and note an April 21, 2026 deadline; these suits create tangible legal and financial overhang. Hagens Berman Alert (GlobeNewswire)
• Negative Sentiment: Recent insider selling: Corcept disclosed a sale by William Guyer (11,767 shares on Mar 20), which may be viewed negatively by some investors despite offsetting director purchases. Insider Sale SEC Filing

Insider Transactions at Corcept Therapeutics

In related news, Director G Leonard Baker, Jr. purchased 100,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, March 17th. The shares were acquired at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the transaction, the director owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. This trade represents a 9.55% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Guyer sold 11,767 shares of Corcept Therapeutics stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $36.01, for a total value of $423,729.67. Following the completion of the transaction, the insider owned 2,231 shares of the company’s stock, valued at $80,338.31. This trade represents a 84.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 60,000 shares of company stock worth $2,241,035. Company insiders own 20.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Pathstone Holdings LLC raised its position in shares of Corcept Therapeutics by 0.8% during the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after acquiring an additional 144 shares in the last quarter. Campbell Newman Asset Management Inc. boosted its holdings in Corcept Therapeutics by 0.5% in the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after purchasing an additional 170 shares during the period. Clearstead Advisors LLC boosted its holdings in Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 193 shares during the period. Gould Capital LLC increased its stake in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 200 shares during the last quarter. Finally, Advisors Asset Management Inc. increased its stake in Corcept Therapeutics by 1.3% during the second quarter. Advisors Asset Management Inc. now owns 18,935 shares of the biotechnology company’s stock valued at $1,390,000 after purchasing an additional 237 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Stock Performance

Corcept Therapeutics stock opened at $38.53 on Friday. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $117.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85. The company has a market capitalization of $4.10 billion, a price-to-earnings ratio of 46.99 and a beta of 0.29. The firm’s fifty day moving average price is $37.47 and its 200 day moving average price is $61.00.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The business had revenue of $202.13 million for the quarter, compared to analyst estimates of $254.94 million. During the same quarter in the prior year, the business earned $0.26 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. On average, research analysts forecast that Corcept Therapeutics will post 1.36 EPS for the current fiscal year.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.